Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | AMPD2 | Q01433 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL371723 | 0.85 | GAA (0.56) | GAATSHRALDH1A1CYP2D6KMT2A | |
| SCHEMBL21806013 | 0.81 | TSHR (0.49) | GAATSHRALDH1A1CYP2D6KMT2A | |
| SCHEMBL11355073 | 0.76 | GAA (0.54) | GAATSHRALDH1A1CYP2D6KMT2A | |
| SCHEMBL431539 | 0.76 | CYP3A4 (0.56) | GAAALDH1A1CYP2D6KMT2AMEN1 | |
| SCHEMBL1792829 | 0.75 | S1PR5 (0.66) | GAAALDH1A1CYP2D6FAAH | |
| SCHEMBL63806 | 0.75 | TSHR (0.63) | TSHRALDH1A1CYP2D6KMT2AMEN1 | |
| SCHEMBL3955531 | 0.75 | TSHR (0.63) | TSHRALDH1A1CYP2D6KMT2AMEN1 | |
| SCHEMBL3210066 | 0.74 | CYP2D6 (0.76) | TSHRALDH1A1CYP2D6KMT2ASIGMAR1 | |
| SCHEMBL27798357 | 0.74 | SIGMAR1 (0.62) | GAATSHRALDH1A1CYP2D6KMT2A | |
| Carbamic Acid SCHEMBL6249677 | 0.74 | TSHR (0.63) | TSHRALDH1A1CYP2D6KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | claimed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355678-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | GAA 3255/4885TSHR 2803/4885ALDH1A1 2072/4885 |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | FLT4, FLT1, MET | GAA 3255/4885TSHR 2803/4885ALDH1A1 2072/4885 |
| US-20080166359-A1 | Methods of using MEK inhibitors | BRAF, NRAS, KRAS | GAA 2414/4885TSHR 3752/4885ALDH1A1 1438/4885 |
| US-11124482-B2 | C-met modulators and methods of use | FLT4, FLT1, MET | GAA 3255/4885TSHR 2803/4885ALDH1A1 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.